Spero Therapeutics, Inc. — Director's Dealing 2021

Nov 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2021-11-11

Reporting Person: Tregoning Kathleen (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-11	Stock Option (right to buy)	$16.91	A	15000	Acquired	2031-11-11	Common Stock (15000)	Direct

Footnotes

F1: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following November 11, 2021, subject to the Reporting Person's continued service as a director through the applicable vesting dates.